Acera Surgical, Inc.
Acera Surgical is a bioscience company commercializing a portfolio of fully synthetic electrospun scaffolds for regenerative medical applications.
- Stage $500K in TTM Revenue
- Industry Nanotechnology
- Location St. Louis, MO, USA
- Currency USD
- Founded January 2013
- Employees 5
- Incorporation Type C-corp
- Website acera-surgical.com
Company Summary
Acera Surgical, Inc. (“Acera”) is a bioscience company commercializing a portfolio of fully synthetic electrospun scaffolds for regenerative medical applications. Acera’s products exhibit a structure similar to native ECM and thus support rapid and effective healing. The FDA cleared Acera’s first product (Cerafix®) in March 2016 and its second product (Restrata) in April 2017, both via 510(k), granting commercial access to markets >$1.2B.
Team
-
Agnes Rey-GiraudChief Executive Officer
Agnès, a former Officer of Express Scripts, was a driving force behind many of the company’s key strategic initiatives and an influential player in the transformation of the company from a $4B to $44B enterprise, serving key roles in Product Dvlmnt, Supply Chain, Corporate Strategy and International Operations. Agnes holds an MBA from the University of Chicago and earned a Master of Science in Mechanical Engineering from ENISE, France.
-
Tamas KovacsSenior Director, Product Management
Prior to joining Acera, Tamas spent 2 years in China as a project manager for Express Scripts, Inc. After earning a bachelor’s degree in Operations Research and Industrial Engineering, Tamas received a Masters of Engineering in Engineering Management, both degrees from Cornell University.
-
Julie CochranChief Operating Officer
Julie earned an MBA from the Stanford Graduate School of Business and graduated summa cum laude with a BSE in both Biomedical Engineering and Electrical Engineering from Duke University. While at McKinsey, Julie served clients throughout the healthcare sector, including pharmaceutical, medical device, biotechnology and payer/provider. She also held multiple roles as a VP at Express Scripts, including Corporate Strategy and Product Dvlmnt/Mgmt.
-
Dr. Matthew MacEwanCo-Founder/Chief Scientific Officer
Matthew is the co-inventor of Acera’s technology and graduated summa cum laude with a degree in BME from Case Western Reserve Univ. with a specialization in polymer biomaterials/biomaterial biocompatibility and received his PhD in BME from Washington University where he also received his MD training. Matthew received multiple entrepreneurship awards, including the 2011 Olin Cup Award & the 2011 LES Global Business Plan Competition Grand Prize.
Advisors
Previous Investors
-
Washington University in St. LouisUnconfirmedPrivate InvestorsUnconfirmedMissouri Technology CorporationUnconfirmed
-
Arch Angels (via Acera Angels LLC)Unconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.